AC
BOLD

Armistice Capital’s Audentes Therapeutics, Inc BOLD Stock Holding History

Armistice Capital’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-636,000
Closed -$17.9M – 95
2019
Q3 		$17.9M Buy
+636,000
New +$21.7M 1.18% 34

Other funds holding BOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Armistice Capital's BOLD Position: Q4 2019 in Review

Armistice Capital sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2019, closing a stake of 636,000 shares — an estimated $17.9M sold.

Armistice Capital first reported a position in BOLD in Q3 2019 and held it in 1 quarter. The position peaked at $17.9M in Q3 2019. 188 funds tracked by Wall St. Rank hold BOLD as of Q4 2019.

  • Armistice Capital reported no remaining Audentes Therapeutics, Inc position as of Q4 2019 after selling out during the quarter.
  • Armistice Capital sold 636,000 Audentes Therapeutics, Inc shares in Q4 2019, an estimated $17.9M.
  • Armistice Capital first reported a position in Audentes Therapeutics, Inc in Q3 2019 and held it in 1 quarter.
  • Armistice Capital's Audentes Therapeutics, Inc position peaked at $17.9M in Q3 2019.
  • 188 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2019.

Based on Armistice Capital's 13F filing for Q4 2019, filed 14 Feb 2020.